Logo

Sanofi Presents Results of Sarclisa (isatuximab) in P-III (IKEMA) Trial for Relapsed Multiple Myeloma at COMy 2022

Share this

Sanofi Presents Results of Sarclisa (isatuximab) in P-III (IKEMA) Trial for Relapsed Multiple Myeloma at COMy 2022

Shots:

  • The P-III (IKEMA) trial evaluating Sarclisa + carfilzomib & dexamethasone vs Kd in 302 patients with relapsed MM across 69 centers spanning 16 countries
  • The results showed an m-PFS of 35.7mos. vs 19.2mos., m-PFS (41.7mos. vs 20.8mos.), time to next treatment (44.9mos.) @25mos., safety & tolerability were consistent with the safety profile of Sarclisa in other clinical trials with no new safety signals, treatment exposure was 30wks. longer, TEAEs of ≥ grade 3 (83.6% vs 73%), serious TEAEs (70.1% vs 59.8%) with no difference after exposure adjustment
  • The results will also be presented at ESMO 2022. Sarclisa was approved in multiple countries in combination with carfilzomib & dexamethasone including in the US & EU for MM

Ref: Sanofi | Image: Sanofi 
 

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions